Tevogen Bio (NASDAQ:TVGN) Receives Buy Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Tevogen Bio (NASDAQ:TVGN) in a research note issued to investors on Monday morning,Benzinga reports. They currently have a $10.00 target price on the stock.

Tevogen Bio Stock Down 1.2%

Shares of TVGN stock opened at $0.9191 on Monday. Tevogen Bio has a 12-month low of $0.2556 and a 12-month high of $3.09. The stock’s 50-day moving average price is $1.12 and its 200-day moving average price is $1.17.

Tevogen Bio (NASDAQ:TVGN) last issued its earnings results on Tuesday, August 19th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.02.

Insider Activity

In other news, CEO Ryan H. Saadi sold 1,438,206 shares of Tevogen Bio stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $1.23, for a total value of $1,768,993.38. Following the sale, the chief executive officer directly owned 116,814,453 shares of the company’s stock, valued at approximately $143,681,777.19. The trade was a 1.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 73.24% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its holdings in shares of Tevogen Bio by 31.2% in the 4th quarter. Geode Capital Management LLC now owns 451,851 shares of the company’s stock valued at $465,000 after acquiring an additional 107,566 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Tevogen Bio by 13.0% in the 4th quarter. Northern Trust Corp now owns 118,415 shares of the company’s stock valued at $122,000 after acquiring an additional 13,595 shares during the last quarter. Nuveen LLC bought a new position in shares of Tevogen Bio in the 1st quarter valued at about $97,000. XTX Topco Ltd bought a new position in shares of Tevogen Bio in the 4th quarter valued at about $55,000. Finally, Barclays PLC lifted its holdings in shares of Tevogen Bio by 39.2% in the 4th quarter. Barclays PLC now owns 45,600 shares of the company’s stock valued at $48,000 after acquiring an additional 12,847 shares during the last quarter.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.